Carmell Therapeutics   Report issue

For profit Phase 3
Founded: Pittsburgh PA United States (2007)

Organization Overview

First Clinical Trial
2019
NCT03826784
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Carmell Therapeutics | Carmell Therapeutics Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

beta-tricalcium phosphate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fractures, Bone (Phase 3)

Tibial Fractures (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1